1. Intranasal Administration of PACAP Is an Efficient Delivery Route to Reduce Infarct Volume and Promote Functional Recovery After Transient and Permanent Middle Cerebral Artery Occlusion
- Author
-
Asma Cherait, Julie Maucotel, Benjamin Lefranc, Jérôme Leprince, David Vaudry, Lebon, Alexis, Différenciation et communication neuronale et neuroendocrine (DC2N), Université de Rouen Normandie (UNIROUEN), Normandie Université (NU)-Normandie Université (NU)-Institut National de la Santé et de la Recherche Médicale (INSERM), University of Algiers 3 : Université d' Alger 3, Plate-Forme de Recherche en Imagerie Cellulaire de Haute-Normandie (PRIMACEN), Normandie Université (NU)-Normandie Université (NU)-Institute for Research and Innovation in Biomedicine (IRIB), Normandie Université (NU)-Normandie Université (NU)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS)-Université de Rouen Normandie (UNIROUEN), Normandie Université (NU)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS)-High-tech Research Infrastructures for Life Sciences (HeRacLeS), and Normandie Université (NU)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS)
- Subjects
Male ,0301 basic medicine ,Nasal cavity ,functional recovery ,Endocrinology, Diabetes and Metabolism ,MESH: Neurotransmitter Agents ,Pharmacology ,infarct volume ,lcsh:Diseases of the endocrine glands. Clinical endocrinology ,cerebral ischemia ,Mice ,Endocrinology ,0302 clinical medicine ,[CHIM] Chemical Sciences ,MESH: Animals ,MESH: Administration, Intranasal ,Middle cerebral artery occlusion ,Original Research ,Neurotransmitter Agents ,MESH: Infarction, Middle Cerebral Artery ,Infarction, Middle Cerebral Artery ,MESH: Neuroprotective Agents ,MESH: Recovery of Function ,pituitary adenylate cyclase-activating polypeptide ,Neuroprotective Agents ,medicine.anatomical_structure ,Infarct volume ,Brain Infarction ,Central nervous system ,Ischemia ,Neuroprotection ,intranasal administration ,03 medical and health sciences ,MESH: Brain Infarction ,MESH: Mice, Inbred C57BL ,medicine ,[CHIM]Chemical Sciences ,Animals ,MESH: Mice ,Administration, Intranasal ,lcsh:RC648-665 ,business.industry ,MESH: Pituitary Adenylate Cyclase-Activating Polypeptide ,Recovery of Function ,medicine.disease ,Functional recovery ,MESH: Male ,Mice, Inbred C57BL ,030104 developmental biology ,Nasal administration ,business ,030217 neurology & neurosurgery - Abstract
International audience; Intranasal (IN) administration appears to be a suitable route for clinical use as it allows direct delivery of bioactive molecules to the central nervous system, reducing systemic exposure and sides effects. Nevertheless, only some molecules can be transported to the brain from the nasal cavity. This led us to compare the efficiency of an IN, intravenous (IV), and intraperitoneal (IP) administration of pituitary adenylate cyclase-activating polypeptide (PACAP) after transient or permanent middle cerebral artery occlusion (MCAO) in C57BL/6 mice. The results show that the neuroprotective effect of PACAP is much more efficient after IN administration than IV injection while IP injection had no effect. IN administration of PACAP reduced the infarct volume when injected within 6 h after the reperfusion and improved functional recovery up to at least 1 week after the ischemia.
- Published
- 2021
- Full Text
- View/download PDF